| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Isobavachalcone targets the Akt signaling pathway as a potent inhibitor. It also inhibits platelet aggregation. By inhibiting Akt signaling, isobavachalcone induces apoptosis in human cancer cells. It inhibits LPS-induced ICAM-1 expression and leukocyte adhesion to brain endothelial cells. Isobavachalcone's anti-inflammatory, anticancer, and neuroprotective effects are mediated through its modulation of multiple signaling pathways.
|
|---|---|
| ln Vitro |
Human adrenal gland proliferation is inhibited by isobavachalcone (6.0-48.0 μM; 72 hours; OVCAR-8, PC3, A549, MCF-7, L-02, and HUVEC cells) therapy. PC3, A549, MCF-7, L-02, and HUVEC cells are all inhibited in growth by isobavachalcone, with IC50 values of 15.06 μM, 32.2 μM, 28.29 μM, 31.61 μM, and 31.3 μM, respectively [1]. Treatment with isobavachalcone (0-18 μM; 72; OVCAR-8 and PC3 cells) for 6 hours results in the Ser of Akt. Apoptosis is caused by isobavachalcone (0-18 μM; 72; OVCAR-8 and PC3 cells) via a mechanism involving caspase and ROS [473 phosphorylation and concentration and time atrophy of GSK3b phosphorylation [1].
In vitro, isobavachalcone is a potent inhibitor of the Akt signaling pathway, inducing apoptosis in human cancer cells. It inhibits OVCAR-8 cell growth with an IC₅₀ of 7.92 μM. The compound inhibits platelet aggregation. It inhibits LPS-induced ICAM-1 expression and leukocyte adhesion to brain endothelial cells. Isobavachalcone possesses anticancer, antimicrobial, anti-inflammatory, antioxidant, and neuroprotective activities. In cell-based assays, isobavachalcone treatment results in apoptosis, reduced inflammation, and neuroprotection. |
| ln Vivo |
Female Kunming mice treated with isobavachalcone (20 mg/kg; i.p.; 0.5–24 hours) develop elevated hypertension that reaches its peak in 1 hour and lasts for 4 hours following maintenance [1].
In vivo, isobavachalcone has been studied for its anticancer, anti-inflammatory, and neuroprotective effects. As a naturally occurring chalcone, it has potential therapeutic applications. However, detailed in vivo efficacy data are limited. The compound is primarily used as a research tool in in vitro studies. Comprehensive in vivo studies are needed to fully characterize its therapeutic potential. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays for isobavachalcone involve measuring its inhibition of Akt signaling pathway activity. The compound's binding to Akt or its effect on Akt phosphorylation is assessed using Western blot or kinase assays. Its anti-inflammatory activity is assessed by measuring the inhibition of ICAM-1 expression or cytokine production. These assays confirm the compound's multi-targeted mechanism.
|
| Cell Assay |
Cell proliferation assay [1]
Cell Types: OVCAR-8, PC3, A549, MCF-7, L-02 and HUVEC Cell Tested Concentrations: 6.0-48.0 μM Incubation Duration: 72 hrs (hours) Experimental Results: Inhibition of proliferation of human cancer cells. . Western Blot Analysis[1] Cell Types: OVCAR-8 or PC3 Cell Tested Concentrations: 0 μM, 6 μM, 12 μM and 18 μM Incubation Duration: 6 hrs (hours) Experimental Results: Concentration- and time-dependent downregulation of Ser- Chapter 473 Phosphorylation of Akt . GSK3b phosphorylation was also inhibited in a concentration- and time-dependent manner. Apoptosis analysis [1] Cell Types: OVCAR-8 cells and PC3 cells Tested Concentrations: 0 μM, 6 μM, 12 μM and 18 μM Incubation Duration: 72 hrs (hours) Experimental Results: Caused a dose-dependent increase in cell apoptosis. In vitro cell-based assays for isobavachalcone evaluate its anticancer, anti-inflammatory, and neuroprotective effects. Cancer cells (e.g., OVCAR-8) are cultured and treated with isobavachalcone, and cell viability is assessed using MTT or CellTiter-Glo assays. Apoptosis is quantified by measuring caspase-3/7 activity or by Annexin V staining. Inflammation is assessed by measuring cytokine production in immune cells stimulated with LPS. These assays confirm the compound's functional activity. |
| Animal Protocol |
Animal/Disease Models: Sevenweeks old specific pathogen-free female Kunming mice (18-22 grams) [1]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip) injection; 0.5, 1, 2, 4, 6, 8, 12, 24 Hourly Experimental Results: Increased blood sugar levels. In vivo animal experiments for isobavachalcone have not been extensively reported. The compound is a naturally occurring chalcone from Psoralea corylifolia. For potential in vivo studies, isobavachalcone can be administered via oral or intraperitoneal routes in animal models of cancer, inflammation, or neurodegeneration. The compound's effects on tumor growth, inflammation, and neurological function would be assessed. Comprehensive in vivo studies are needed. |
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for isobavachalcone are limited. The compound has a molecular weight of 324.37 g/mol and is a yellow to light brown powder. It is a naturally occurring chalcone with low water solubility. The compound's metabolic stability, half-life, and bioavailability have not been fully characterized. Comprehensive ADME studies are needed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of isobavachalcone has not been extensively characterized. As a natural product, it is generally considered to have low toxicity. However, the compound should be handled with appropriate safety precautions in the laboratory. For research use only, not for human therapeutic use without proper authorization. Comprehensive toxicological studies are needed.
|
| References | |
| Additional Infomation |
Isopavalchalcone is a chalcone compound with the structure trans-chalcone, substituted with hydroxyl groups at the 4', 2', and 4' positions and an isopentenyl group at the 3' position. It possesses antibacterial, platelet aggregation-inhibiting, and metabolite-like effects. It is a polyphenol belonging to the chalcone class. Its function is related to that of trans-chalcone. Isopavalchalcone has been reported to be found in mulberry (Morus cathayana), Hypericum geminiflorum, and other organisms with relevant data. See also: Angelica keiskei top (partial).
Isobavachalcone (Corylifolinin) is a naturally occurring chalcone isolated from Psoralea corylifolia. It is a potent inhibitor of the Akt signaling pathway, inducing apoptosis in human cancer cells. Isobavachalcone inhibits OVCAR-8 cell growth with an IC₅₀ of 7.92 μM. It possesses anticancer, antimicrobial, anti-inflammatory, antioxidant, and neuroprotective activities. Isobavachalcone is a research tool and has not progressed to clinical trials. |
| Molecular Formula |
C20H20O4
|
|---|---|
| Molecular Weight |
324.376
|
| Exact Mass |
324.136
|
| CAS # |
20784-50-3
|
| Related CAS # |
Isobavachalcone; 20784-50-3
|
| PubChem CID |
5281255
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
549.0±50.0 °C at 760 mmHg
|
| Flash Point |
299.9±26.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| Source |
Originated from plants: Leguminosae Psoralea corylifolia L.
Originated from plants: Leguminosae Glycyrrhiza uralensis Fisch. |
| LogP |
5.21
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
470
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=CCC1=C(C=CC(=C1O)C(=O)/C=C/C2=CC=C(C=C2)O)O)C
|
| InChi Key |
DUWPGRAKHMEPCM-IZZDOVSWSA-N
|
| InChi Code |
InChI=1S/C20H20O4/c1-13(2)3-9-16-19(23)12-10-17(20(16)24)18(22)11-6-14-4-7-15(21)8-5-14/h3-8,10-12,21,23-24H,9H2,1-2H3/b11-6+
|
| Chemical Name |
(E)-1-(2,4-dihydroxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
|
| Synonyms |
CorylifolininIsobavachalcone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~11 mg/mL (~33.91 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (20.8 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0828 mL | 15.4140 mL | 30.8280 mL | |
| 5 mM | 0.6166 mL | 3.0828 mL | 6.1656 mL | |
| 10 mM | 0.3083 mL | 1.5414 mL | 3.0828 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
